Browse

The British drugmaker's third acquisition this year gives it two experimental lung cancer drugs under FDA review that it hopes will support a franchise.

The one law of CEO pay packages: They keep getting bigger. Yesterday, we published the first installment of Endpoints News’ annual biopharma compensation project. Following our analysis of the indu…

Another wave of scrutiny has hit WuXi AppTec through its re-inclusion in the Pentagon’s updated list of companies that have ties to the Chinese military. With its appearance on the list ...